ネオアンチゲン標的治療薬市場：適応疾患別、ネオアンチゲンタイプ別、免疫療法タイプ別、投与経路別-2023-2030年の世界予測

ネオアンチゲン標的治療薬の世界市場は、2023年に33億1,282万米ドル、CAGR 38.50%で大きく成長し、2030年には324億1,890万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のネオアンチゲン標的治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.ネオアンチゲン標的治療薬の世界市場規模および予測は？

2.予測期間中、世界のネオアンチゲン標的治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.ネオアンチゲン標的治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.ネオアンチゲン標的治療薬の世界市場における競争戦略は？

5.ネオアンチゲン標的治療薬の世界市場における技術動向と規制の枠組みは？

6.ネオアンチゲン標的治療薬の世界市場における主要ベンダーの市場シェアは？

7.ネオアンチゲン標的治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ネオアンチゲン標的治療薬の人気の高まり
    • がん患者数の急増
    • 世界中で高齢者人口が増加
    • ヘルスケアインフラの開発
  • 抑制要因
    • ネオアンチゲン標的治療薬に関連する副作用
  • 機会
    • がん治療における技術の進歩
    • 償還計画などの政府投資の増加
  • 課題
    • ネオアンチゲン同定の課題
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 ネオアンチゲン標的治療薬市場対象疾患別

• 骨がん
• 結腸直腸がん
• 婦人科がん
• 非小細胞肺がん
• 腎細胞がん

第7章 ネオアンチゲン標的治療薬市場ネオアンチゲンの種類別

• 既製のネオアンチゲン
• パーソナライズされたネオアンチゲン

第8章 ネオアンチゲン標的治療薬市場免疫療法の種類別

• 樹状細胞ワクチン
• DNA/RNAベースのワクチン
• タンパク質/ペプチドベースのワクチン
• TILベースの治療法

第9章 ネオアンチゲン標的治療薬市場：投与経路別

• 皮内
• 静脈内
• 皮下

第10章 南北アメリカのネオアンチゲン標的治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のネオアンチゲン標的治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのネオアンチゲン標的治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第14章 掲載企業一覧

第15章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. NEOANTIGEN TARGETED THERAPIES MARKET RESEARCH PROCESS
• FIGURE 2. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2022 VS 2030
• FIGURE 3. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2022 VS 2030 (%)
• FIGURE 5. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2022 VS 2030 (%)
• FIGURE 6. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2022 VS 2030 (%)
• FIGURE 7. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
• FIGURE 8. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. NEOANTIGEN TARGETED THERAPIES MARKET DYNAMICS
• FIGURE 10. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. NEOANTIGEN TARGETED THERAPIES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 5. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 11. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY OFF-THE-SHELF NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 14. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA / RNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PROTEIN / PEPTIDE-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TIL-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 19. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 151. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 191. NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 192. NEOANTIGEN TARGETED THERAPIES MARKET LICENSE & PRICING

The Global Neoantigen Targeted Therapies Market is forecasted to grow significantly, with a projected USD 3,312.82 million in 2023 at a CAGR of 38.50% and expected to reach a staggering USD 32,418.90 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Neoantigen Targeted Therapies Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Neoantigen Targeted Therapies Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Target Disease Indication, market is studied across Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, and Renal Cell Carcinoma. The Colorectal Cancer is projected to witness significant market share during forecast period.

Based on Neoantigens Type, market is studied across Off-the-Shelf Neoantigens and Personalized Neoantigens. The Off-the-Shelf Neoantigens is projected to witness significant market share during forecast period.

Based on Immunotherapy Type, market is studied across Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, and TIL-Based Therapies. The TIL-Based Therapies is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Intradermal, Intravenous, and Subcutaneous. The Intravenous is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Neoantigen Targeted Therapies Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Neoantigen Targeted Therapies Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neoantigen Targeted Therapies Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neoantigen Targeted Therapies Market?

4. What is the competitive strategic window for opportunities in the Global Neoantigen Targeted Therapies Market?

5. What are the technology trends and regulatory frameworks in the Global Neoantigen Targeted Therapies Market?

6. What is the market share of the leading vendors in the Global Neoantigen Targeted Therapies Market?

7. What modes and strategic moves are considered suitable for entering the Global Neoantigen Targeted Therapies Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Neoantigen Targeted Therapies Market, by Target Disease Indication, 2022 vs 2030
• 4.3. Neoantigen Targeted Therapies Market, by Neoantigens Type, 2022 vs 2030
• 4.4. Neoantigen Targeted Therapies Market, by Immunotherapy Type, 2022 vs 2030
• 4.5. Neoantigen Targeted Therapies Market, by Route of Administration, 2022 vs 2030
• 4.6. Neoantigen Targeted Therapies Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in the popularity of neoantigen targeted therapies
    • 5.1.1.2. Surge in number of cancer patients
    • 5.1.1.3. Increase in the geriatric population across the globe
    • 5.1.1.4. Developing healthcare infrastructure
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with neoantigen targeted therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancement in the cancer treatment
    • 5.1.3.2. Increasing government investment such as reimbursement plan
  • 5.1.4. Challenges
    • 5.1.4.1. Challenges of neoantigen identification
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Neoantigen Targeted Therapies Market, by Target Disease Indication

• 6.1. Introduction
• 6.2. Bone Cancer
• 6.3. Colorectal Cancer
• 6.4. Gynecological Cancer
• 6.5. Non-Small Cell Lung Cancer
• 6.6. Renal Cell Carcinoma

7. Neoantigen Targeted Therapies Market, by Neoantigens Type

• 7.1. Introduction
• 7.2. Off-the-Shelf Neoantigens
• 7.3. Personalized Neoantigens

8. Neoantigen Targeted Therapies Market, by Immunotherapy Type

• 8.1. Introduction
• 8.2. Dendritic Cell Vaccines
• 8.3. DNA / RNA-Based Vaccines
• 8.4. Protein / Peptide-based Vaccines
• 8.5. TIL-Based Therapies

9. Neoantigen Targeted Therapies Market, by Route of Administration

• 9.1. Introduction
• 9.2. Intradermal
• 9.3. Intravenous
• 9.4. Subcutaneous

10. Americas Neoantigen Targeted Therapies Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Neoantigen Targeted Therapies Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Neoantigen Targeted Therapies Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing